Hepatic monoamine oxidase B is involved in endogenous geranylgeranoic acid synthesis in mammalian liver cells

Yuki Tabata¹ and Yoshihiro Shidoji¹

¹Molecular and Cellular Biology, Graduate School of Human Health Science, University of Nagasaki, Nagayo, Nagasaki 851-2195, Japan

Correspondence: Yoshihiro Shidoji: Molecular and Cellular Biology, Graduate School of Human Health Science, University of Nagasaki, Nagayo, Nagasaki 851-2195, Japan: shidoji@sun.ac.jp

Running title: Hepatic MAOB is involved in biosynthesis of GGA

Abbreviations: ADH, alcohol dehydrogenase; Fal, farnesal; FOH, farnesol; FPP, farnesyl diphosphate; GGA, geranylgeranoic acid; GGal, geranylgeranial; GGOH, geranylgeraniol; GGPP, geranylgeranyl diphosphate; GOH, geraniol; MAOB, monoamine oxidase B; MVA, mevalonate; PCYOX1, prenylcysteine oxidase 1; TCP, tranylcypromine; ZAA, zaragozic acid A
Abstract

Geranylgeranoic acid (GGA) originally was identified in some animals and has been developed as an agent for preventing second primary hepatoma. We previously have identified GGA also as an acyclic diterpenoid in some medicinal herbs. Recently, we reported that in human hepatoma-derived HuH-7 cells, GGA is metabolically labeled from $^{13}$C-mevalonate. Several cell-free experiments have demonstrated that GGA is synthesized through geranylgeranal by oxygen-dependent oxidation of geranylgeraniol (GGOH), but the exact biochemical events giving rise to GGA in hepatoma cells remain unclear. Monoamine oxidase B (MAOB) has been suggested to be involved in GGOH oxidation. Here, using two human hepatoma cell lines, we investigated whether MAOB contributes to GGA biosynthesis. Using either HuH-7 cell lysates or recombinant human MAOB, we found (i) that the MAO inhibitor tranylcypromine dose-dependently down-regulates endogenous GGA levels in HuH-7 cells, and (ii) that siRNA-mediated MAOB silencing reduces intracellular GGA levels in HuH-7 and Hep3B cells. Unexpectedly, however, CRISPR/Cas9-generated MAOB-knockout human hepatoma Hep3B (MAOB-KO) cells had GGA levels similar to those in MAOB wild-type cells. A sensitivity of GGA levels to siRNA-mediated MAOB down-regulation was recovered when the MAOB-KO cells were transfected with a MAOB-expression plasmid, suggesting that MAOB is the enzyme primarily responsible for GGOH oxidation and that some other latent metabolic pathways may maintain endogenous GGA levels in the MAOB-KO hepatoma cells. Along with the previous findings, these results provide critical insights into the biological roles of human MAOB and provide evidence that hepatic MAOB is involved in endogenous GGA biosynthesis via GGOH oxidation.
Keywords: cancer, cancer prevention, isoprenoids, liver, mass spectrometry, mevalonate pathway, retinoids, geranylgeranoic acid (GGA), diterpenoid, monoamine oxidase B (MAOB)
Introduction

Geranylgeranoic acid (all-trans 3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenoic acid or GGA) is a compound that was first recognized as a mevalonate (MVA)-derived metabolite in cell-free homogenates of the bovine retina in 1983 (1), then in a parasitic worm in 1993 (2), consisting of 4-isoprene units linked in a tail-to-head manner. GGA and its didehydro derivative were shown to be potent ligands for nuclear retinoid receptors (3), so these isoprenoid compounds have been developed as preventive agents against second primary hepatoma (4, 5). In the past, we reported that GGA is a natural compound present in some medicinal herbs (6). Recently, we found that the GGA, is not only present in plant tissues, but was also endogenously present in various organs of male Wistar rats. Its biosynthesis from MVA via farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP) is also confirmed in human hepatoma derived cells (7). A previous study reported that GGPP added in rat liver homogenates is converted to geranylgeraniol (GGOH) by geranylgeranyl pyrophosphatase (GGPPase), which is most active at physiologic pH and highly specific for GGPP (8). GGOH produced by GGPPase had been thought to be oxidized to geranylgeranal (GGal) by cytosolic alcohol dehydrogenase (ADH) in the presence of NAD$^+$ (9) and GGal had been supposed to be further oxidized to GGA by non-specific aldehyde dehydrogenase (9). Indeed, we have confirmed that the enzymatic conversion from GGal to GGA is highly dependent on exogenous NAD$^+$ in rat liver homogenates (10) and human hepatoma-derived HuH-7 cell lysates (11). However, we found that a putative enzyme in either rat liver or HuH-7 cells involved in the oxidation of GGOH to GGal did not require any exogenous NAD$^+$ in the cell-free system (10, 11). The GGOH oxidation
activity was highest in the mitochondrial fraction prepared from rat liver homogenates (10).

Taking account that the mitochondrial enzyme was sensitive to tranyleypromine (TCP), an inhibitor against monoamine oxidases (11), we have reasonably speculated that a certain member of the monoamine oxidase family is involved in GGOH oxidation to GGal in the process of GGA biosynthesis (10, 11). We so far have the following three lines of evidence for monoamine oxidase B (MAOB) as a GGOH-oxidizing enzyme; 1) HuH-7 cell lysate or rat liver homogenate enzyme does not require the exogenous NAD\(^+\) to produce GGal, 2) molecular oxygen solubilized in the reaction mixture is consumed upon addition of GGOH into HuH-7 cell lysates as an enzyme source, and 3) the recombinant human MAOB protein actively oxidizes GGOH to GGal (11).

MAOB, a flavin enzyme located to the outer mitochondrial membrane, generally degrades phenylethylamine and dopamine in the central nervous system (12). When these substrates are oxidized by MAOB, molecular oxygen is consumed and reactive oxygen species such as hydrogen peroxide are generated. Therefore, an increase in the expression level of MAOB in the brain is expected to damage the nervous system due to the reactive oxygen species produced (13). In fact, the expression of MAOB is increased in Alzheimer's disease and Parkinson's disease (14, 15), and MAOB inhibitors have been investigated as treatments for these diseases (16, 17). In contrast to the diverse MAOB studies in the nervous system, the physiological role of MAOB in the liver is not clearly defined, despite the tissue levels of MAOB mRNA expression being not only higher than those in the central nervous system, but also highest among all human organs (18). At present, the liver MAOB enzyme is considered to contribute to the decomposition of xenobiotics because the liver is a major organ that contributes to drug metabolism and MAOB shows
relatively broad substrate specificity for aromatic amines (19). In this context, the physiological substrate of liver MAOB has not yet been clearly elucidated. Therefore, if we can show that GGOH is an endogenous substrate of hepatic MAOB, as mentioned earlier, we will add a new perspective on the physiological role of hepatic MAOB.

By using an MAO inhibitor and siRNAs to inhibit and downregulate the cellular MAOB enzyme activity, here, we demonstrate that hepatic MAOB is involved in the maintenance of the intracellular GGA level in human hepatoma-derived cells. To ensure that MAOB is involved in GGA biosynthesis more reliably, we performed knockout of the MAOB gene using the CRISPR/Cas9 plasmids in human hepatoma cells, but, unexpectedly, the intracellular GGA content of MAOB-knockout (KO) cells was almost the same as that of the wild-type cells. However, when the MAOB-KO cells were back-transfected with MAOB expression plasmid, MAOB siRNA-mediated downregulation of the endogenous GGA level was recovered. In other words, when MAOB is expressed normally in human hepatocytes, the intracellular level of GGA is dependent on MAOB activity. The possibility that enzymes other than MAOB in MAOB-KO cells are involved in maintaining the intracellular GGA content is also described.
Materials and Methods

Chemicals

All-trans GGA and 2,3-dihydroGGA were prepared by Kuraray Co. (Okayama, Japan) and Kowa Pharmaceutical (Tokyo, Japan). GGOH was provided from Eisai Foods (99% pure, Tokyo, Japan). Acetonitrile (LC/MS grade), ethanol, farnesol (FOH), geraniol (GOH), hygromycin, Dulbecco’s phosphate buffered saline, without calcium chloride and magnesium chloride, suitable for cell culture (PBS (-)), TCP were all purchased from Sigma Aldrich (St. Louis, MO, USA). Citral, methanol and Dulbecco’s modified Eagle medium (DMEM, high glucose) were from Wako Pure Chemical Industries (Osaka, Japan). Chloroform was obtained from Kanto Chemical Co. (Tokyo, Japan). FBS was bought from HyClone, Thermo Fisher (Tokyo, Japan). Zaragozic acid A (ZAA, an inhibitor of squalene synthase) was provided from Merck (Darmstadt, Germany). All chemicals other than those stated above were of reagent grade.

Cell Culture

Human hepatoma-derived HuH-7 and Hep3B cells were maintained with DMEM containing 5% FBS at 37°C in a humidified atmosphere of 5% CO₂.

Treatment of HuH-7 cells with MAO inhibitor

HuH-7 cells (5 × 10⁵ cells/dish, in a 10-cm diameter dish) were inoculated and cultured in DMEM containing 5% FBS for 24 h; thereafter, the medium was replaced with FBS-free DMEM 1 day before TCP
treatment. After 24-h treatment of the cells with different concentrations (0 - 100 µM) of TCP or with 100 µM of TCP + 25 µM GGOH, the cells were harvested using a plastic cell lifter (Nunc, Roskilde, Denmark) and the cellular GGA was quantitatively measured using LC/MS/MS as described below. IC$_{50}$ of TCP on the endogenous GGA levels was calculated using GraphPad Prism version 7 for Windows (GraphPad Software, La Jolla, CA).

**Transfection with siRNA**

Ready-made siRNAs for the *MAOB, MAOA, ADH1A*, and prenylcysteine oxidase1 (*PCYOX1*) genes were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The siRNAs are included three pairs of specific about 20-nt siRNAs designed to knock down the expression of each specific gene (see supplemental Table S1). For transfection, HuH-7 cells or Hep3B cells were inoculated on 30-mm dishes at a density of 4 × 10$^4$ cells/dish. On the next day, 80 pmol of each siRNA were transfected using Lipofectamine® 2000 (Thermo Fisher Scientific). After 72-h incubation, total RNA was prepared from cells to measure the cellular mRNA levels of each gene. Cells incubated for an additional 48 h (120 h in total after transfection) and used for LC/MS/MS quantification of intracellular GGA.

In addition, after HuH-7 cells were incubated with *MAOB* siRNA for 96 h, the cells were incubated for another 24 h in the 25 µM GGOH or 15 µM ZAA.

**Knockout of the MAOB gene in hepatoma cells by using the CRISPR/Cas9 system**

HuH-7 or Hep3B cells (3 × 10$^4$ cells/dish, in a 30-mm-diameter dish) were transfected with 1 µg MAOB
CRISPR/Cas9 KO plasmids and 1 µg HDR plasmids (Santa Cruz Biotechnology). After an approximately 2-w screening with 2 µg/mL puromycin, Hep3B, but no HuH-7 cell clones were established by confirming RFP fluorescence on a laser-scanning confocal fluorescence microscope (LSM-700, Carl Zeiss, Berlin, Germany, see supplemental Fig. S1) and a lack of both MAOB mRNA expression using the RT-qPCR method and the MAOB protein expression using the western blotting method were confirmed in these Hep3B/MAOB-KO cells.

**Back-transfection of the MAOB gene into Hep3B/MAOB KO cells**

Hep3B/MAOB KO cells (3 × 10⁴ cells/dish, in a 30-mm-diameter dish) were transfected with 1 µg human MAOB gene ORF cDNA clone expression plasmid (Sino Biological, Beijing, China). After an approximately 2-w selection with 200 µg/mL hygromycin, re-expression of both MAOB mRNA using the RT-qPCR method and MAOB protein using the western blotting method were confirmed in Hep3B/MAOB-KO/TG cells.

**RT-qPCR**

Total RNA was prepared from each cell culture using the Fastgene™ RNA Basic kit (Nippon Genetics, Tokyo, Japan). For cDNA synthesis, Fastgene™ Scriptase II (Nippon Genetics) was used according to the manufacturer’s instructions. Real-time PCR was performed using LightCycler FastStart DNA MasterPLUS SYBR Green I (Roche Diagnostics, Tokyo, Japan) on a LightCycler 96 (Roche). Gene expression levels were analyzed using the 2−ΔΔCt method. Primer sequences and real-time PCR settings used in this study are
presented in supplemental Tables S2–S4.

**Immunoblotting**

Proteins were prepared from the cells with RIPA lysis buffer (Merck Millipore, Tokyo, Japan) containing protease inhibitors (cOmplete™ Protease Inhibitor Cocktail, Roche Diagnostic) and the solubilized proteins were quantified by Bradford assay (Bio-Rad, Hercules, CA, USA). Equal amounts (10 µg) of protein per sample were separated by Mini-PROTEAN TGX precast gels (Bio-Rad) and transferred onto polyvinylidene fluoride membranes. Horseradish peroxidase-labeled secondary antibodies (GE Healthcare, Tokyo, Japan) were detected with an ECL plus western blotting detection system (GE Healthcare) or a SuperSignal™ West Femto maximum sensitivity substrate (Thermo Fisher Scientific) using an ImageQuant LAS 4000 (GE Healthcare).

**Chemical synthesis and purification of GGal, farnesal (Fal) and geranial (Gal)**

GGOH (29 mg), FOH (22 mg) or GOH (15 mg) were each treated with 300 mg of active MnO₂ (Sigma Aldrich) in 3 mL of chloroform at 40°C for 48 h. The reaction mixture was centrifuged at 300 × g for 10 min to remove pellets. The chloroform extracts containing each aldehyde were dried under a nitrogen gas stream and dissolved in ethanol and purified by chromatography with a LiChroprep RP-18 column (2.5 × 31 cm, Merck). The mobile phase was methanol at a flow rate of 2.0 mL/min. Each purified aldehyde was dried under nitrogen gas and dissolved in ethanol. Each synthesized aldehyde was monitored by its characteristic ultraviolet absorption spectrum at 245 nm with citral as a standard and further use for
LC/MS/MS calibration as a standard for each aldehyde.

**Enzyme assays**

Aliquots of 3–100 µM GGOH, FOH or GOH were incubated at 37°C with the recombinant human MAOB protein (0.15 µg, >85% pure, Active Motif, Carlsbad, CA) in a final volume of 100 µL H₂O. The reaction was then stopped by chilling on ice, and the reaction mixture was diluted with 9 vol of ethanol. The resultant ethanolic extract was filtered through a Cosmonice Filter S cartridge (0.45 µm) prior to the analyses of GGal, Fal and Gal by LC/MS/MS. The Km for each substrate was calculated using GraphPad Prism 7.

**Lipid extraction and quantitative measurement of the cellular GGA**

HuH-7 or Hep3B cells and the conditioned medium were separately collected in each tube by centrifugation (200 × g, 8 min). To extract the total cellular lipids, the cell pellets were added to chloroform/methanol (2:1 v/v; 20-fold volumes over cell volume) and sonicated on ice (three times; each 30 s). After standing overnight at room temperature and being centrifuged (200 × g, 8 min), the supernatant was transferred to a screw-capped glass tube and evaporated to dryness under a nitrogen stream. The residues were dissolved with 100 µL of ethanol and filtered through a Cosmonice Filter S cartridge (0.45 µm) just prior to LC/MS/MS analysis.

**LC/MS/MS analysis**

GGA was detected by the procedures as described in our previous study (7). The chromatographic run to
measure GGOH and GGal was operated by linear gradients between solution A (milli-Q water containing 0.1% formic acid) and solution B (acetonitrile containing 0.1% formic acid). The elution was conducted at a constant flow rate of 0.30 mL/min as follows: 0–12 min, isocratic 74% B; 2–13 min, a linear ascending gradient from 74% B to 100% B; 13–18 min, 100% B; 18–19 min, a linear descending gradient from 100% B to 74% B; 19–22 min, 74% B. The specific combination of the molecular ion and fragment ion, cone voltage and collision cell energy for each compound are listed in supplemental Table S5. Other conditions were the same as the previous procedure (7).

Statistical analysis

Statistical comparisons were performed using a t-test or ANOVA with post hoc Scheffe test where appropriate. All data, unless specified, are presented as mean ± SE, with a statistically significant difference defined as p < 0.05.
Results

Inhibition of the biosynthesis of cellular GGA with tranylcypromine (TCP)

First, we confirmed whether TCP, an inhibitor of MAOs, worked as a micromolar inhibitor of GGA biosynthesis in a cell culture system. Fig. 1A clearly shows that TCP added in the culture medium decreased the cellular level of endogenous GGA in HuH-7 cells in a dose-dependent manner with an apparent IC₅₀ of approximately 33 μM. Furthermore, 100 μM TCP not only decreased the endogenous GGA (Fig. 1B and C), but also suppressed the conversion of exogenously added GGOH to GGA in cultured HuH-7 cells (Fig. 1D and E).

Downregulation of cellular GGA by MAOB siRNA

Even though TCP decreased the cellular level of both endogenous GGA and exogenous GGOH-derived GGA in HuH-7 cells, we cannot exclude a possibility that some other TCP-sensitive enzymes such as MAOA and cytochrome P450 (P450, CYP) enzymes are involved in the biosynthesis of GGA. Therefore, we performed knockdown of the MAOB gene in HuH-7 cells using MAOB siRNA. The MAOB mRNA levels in HuH-7 cells transfected with MAOB siRNA were significantly decreased 72 h after the transfection (Fig. 2A), followed by a significant decrease in endogenous GGA at 120 h (siCtrl 8.95 ± 0.74 pmol/g; siMAOB 2.22 ± 0.18 pmol/g, p < 0.05; their representative LC/MS/MS chromatograms are shown in Fig. 2B). Furthermore, a dramatic increase in the intracellular GGA level induced by the exogenous GGOH was significantly suppressed by MAOB knockdown (siCtrl 205.14 ± 7.36 pmol/g; siMAOB 77.19 ± 3.36 pmol/g,
p < 0.05; see Fig. 2C). In addition, *MAOB* knockdown significantly suppressed the squalene synthase inhibitor zaragozic acid A (ZAA)-induced accumulation of endogenous GGA (*siCtrl* 44.23 ± 1.36 pmol/g; *siMAOB* 13.37 ± 2.14 pmol/g, p < 0.05; the chromatograms are shown in Fig. 2D).

According to the literature (9, 11, 20, 21), MAOA, PCYOX1 and ADH1A are potential enzymes that generate GGal, a direct precursor of GGA (Fig. 3A). Hence, here, we knocked down each gene encoding these enzymes, then measured the amount of endogenous GGA in each knockdown cell. Although the transfection of *MAOA* siRNA, *PCYOX1* siRNA, or *ADH1A* siRNA significantly reduced each gene mRNA level compared with negative control siRNA 72 h after transfection (Fig. 3B, C and D), the cellular levels of endogenous GGA in HuH-7 cells were not decreased in the *MAOA*-siRNA- (9.23 ± 0.68 pmol/g) and *ADH1A*-siRNA- (8.97 ± 0.72 pmol/g) treated cells and, unexpectedly, increased in the *PCYOX1* siRNA- (18.76 ± 2.32 pmol/g, p < 0.05) treated cells at 120 h (Fig. 3E), which is in stark contrast to the case of the *MAOB* knockdown (Fig. 2B). When the relative cellular level of *MAOB* mRNA in each siRNA-treated cell was examined, the *MAOB* expression level was significantly increased by *PCYOX1* siRNA treatment (Fig. 3F). When the intracellular levels of endogenous GGA were plotted against *MAOB* mRNA levels in these cells, a strong correlation was detected between endogenous GGA and *MAOB* mRNA levels ($r^2 = 0.8465$, Fig. 3G).

*Catalytic activity of recombinant human MAOB in the oxidation of GGOH to GGal*

Because the results so far obtained in the present study strongly indicate that the MAOB enzyme is involved in GGA biosynthesis, we next decided to examine whether recombinant human MAOB protein is able to
catalyze the oxidation reaction of acyclic isoprenols by increasing the isoprene unit from 2 to 4 to produce the corresponding aldehydes. As a result, MAOB had no ability to oxidize GOH (C\textsubscript{10}-acyclic monoterpenol, Fig. 4A), but undoubtedly produced Fal (Fig. 4B) from FOH (C\textsubscript{15}-acyclic sesquiterpenol) and GGal (Fig. 4C) from GGOH (C\textsubscript{20}-acyclic diterpenol). Then, kinetic analysis using increasing concentrations of GGOH or FOH as a substrate was performed. As shown in Fig. 4D, a reaction that oxidizes GGOH to GGal showed Michaelis–Menten-type kinetics (Fig. 4D) and the $K_m$ value of the recombinant human MAOB was calculated to be $34.34 \pm 5.35 \mu$M for GGOH, which is in the range of those of rat hepatic (10) and human hepatoma GGOH oxidase (11). The kinetic analysis also demonstrated that the $K_m$ value was $35.22 \pm 7.77 \mu$M for FOH, which is an established inhibitor that competitively inhibits MAOB activity (22–24).

Although the same amount of the recombinant protein was used in the enzyme assay, $V_{max}$ was calculated to be $72.51 \pm 6.87$ pmol/h for FOH and $102.2 \pm 6.77$ pmol/h for GGOH (Fig. 4D), indicating that the turnover number should be 1.4-times greater for GGOH than for FOH.

**MAOB gene knockout by the CRISPR/Cas9-HDR system and the resultant cellular endogenous GGA changes**

From the above results, we were convinced that MAOB is at least partly involved in GGA biosynthesis in HuH-7 cells. However, the above knockdown experiments just showed transient changes, so we next attempted to induce stable depletion of endogenous GGA in human hepatoma cells by establishing MAOB knockout cell clones using the CRISPR/Cas9-HDR system. Because MAOB knockout cells could not be established in HuH-7 cells by puromycin selection after several trials, another human hepatoma-derived...
cell line, Hep3B, which does not harbor any translocation in the X chromosome was used because the
MAOB gene is located on the X chromosome. A puromycin-resistant clone of Hep3B was successfully
obtained and it dramatically reduced MAOB expression at both the mRNA and protein levels (Fig. 5A and
B). However, unexpectedly, the endogenous GGA of the knockout cells (Hep3B/MAOB-KO, 11.82 ± 0.84
pmol/g) did not decrease at all compared with the wild-type Hep3B cells (Hep3B/MAOB-WT, 12.51 ± 0.82
pmol/g) (Fig. 5C).

To exclude the possibility that a MAOB siRNA-induced reduction of the endogenous GGA level
in HuH-7 cells was due to its off-target effect, we conducted further knockdown experiments using the
MAOB siRNA in Hep3B/MAOB-KO and Hep3B/MAOB-WT. The MAOB siRNA induced a significant
decrease in MAOB mRNA levels followed by a significant decrease in the intracellular GGA also in
Hep3B/MAOB-WT (siCtrl 12.32 ± 0.77 pmol/g; siMAOB 5.50 ± 0.43 pmol/g, p<0.05). However, the MAOB
siRNA did not further suppress the cellular MAOB mRNA level that was hardly expressed in the knockout
cells (Fig. 5D), nor did it cause a decrease in endogenous GGA of Hep3B/MAOB-KO (siCtrl 12.78 ± 0.86
pmol/g; siMAOB 12.07.50 ± 0.44 pmol/g, Fig. 5E), suggesting that the MAOB siRNA-induced reduction of
endogenous GGA was not due to its off-target effect in both HuH-7 and Hep3B cells. Next, to investigate
another possibility that a metabolic redundancy of GGA biosynthesis by other enzyme(s) was evoked in the
Hep3B/MAOB-KO cells, we conducted further knockdown experiments using each siRNA of some
potential enzymes (shown in Fig. 3A) that may produce GGa in Hep3B/MAOB-KO and Hep3B/MAOB-
WT. As for other enzymes potentially involved in GGA biosynthesis, efficient knockdown of each gene did
not cause any decrease in endogenous GGA either in Hep3B/MAOB-WT or Hep3B/MAOB-KO (see
supplemental Fig. S2).

**Back-transfection of the MAOB gene into MAOB knockout cells restores the MAOB dependence of intracellular GGA**

Finally, to understand how tightly the MAOB gene is linked to metabolic maintenance of the intracellular level of endogenous GGA, Hep3B/MAOB-KO/TG cells were established by transfecting Hep3B/MAOB-KO with the MAOB gene expression plasmid. The back-transfection of the MAOB gene into the KO cells restored the MAOB protein level in the KO cells to the level of the wild-type cells (Fig. 6A), in accordance with the cellular MAOB mRNA levels (Fig. 6B). Knockdown of the transgenic MAOB gene in Hep3B/MAOB-KO/TG cells with the MAOB siRNA significantly reduced the cellular level of the MAOB mRNA level (Fig. 6B) as well as the endogenous GGA level (siCtrl 13.28 ± 2.61 pmol/g; siMAOB 5.06 ± 1.48 pmol/g, p<0.05, Fig. 6C). Regarding the nature of wild-type cells (MAOB-WT), of which MAOB siRNA reduces intracellular GGA content, the knockout cells (MAOB-KO) were rescued to the same extent as wild-type cells by back-transfection of the MAOB gene into the knockout cells (MAOB-KO/TG), as clearly illustrated in Fig. 6D.
Discussion

In the present study, we provide concrete evidence that hepatic MAOB is involved in the biosynthesis of GGA, which is believed to prevent hepatocarcinogenesis. Reduction of MAOB activity by either inhibitor TCP or introducing its siRNA significantly reduced the endogenous GGA level in human hepatoma cells. However, the amount of intracellular GGA was not reduced in MAOB knockout (Hep3B/MAOB-KO) cells compared with MAOB wild-type (Hep3B/MAOB-WT) cells. Interestingly, back-transfection of the MAOB gene into Hep3B/MAOB-KO cells completely restored the MAOB siRNA-mediated reduction of endogenous GGA, strongly suggesting that the MAOB gene is the enzyme primarily responsible for maintenance of the endogenous GGA level in human hepatoma cells.

As described in the Introduction, we recently reported that, among rat organs, endogenous GGA is rich in the liver and, in human hepatoma derived cells, its biosynthesis from MVA via FPP and GGPP was confirmed by isotopomer spectral analysis (7). However, at the start of our GGA research, GGA was chemically synthesized as a preventive drug for second primary hepatoma together with peretinoin or 4,5-didehydroGGA, which was indeed evaluated in several placebo-controlled randomized clinical trials with positive results (4, 5, 25, 26). Then, we reported the natural occurrence of GGA in several medicinal herbs (6). In 2019, we reported that endogenous GGA can be metabolically labeled from $^{13}$C-MVA via $^{13}$C-GGPP in the MVA pathway in mammalian cells (7). GGPP was reported to be directly converted to alcoholic GGOH by GGPPase in rat liver microsomes (8). Although GGOH was first reported to be oxidized by ADH (9), we have provided several lines of evidence for the possibility that MAOB may catalyze the oxidation of GGOH to GGal (10, 11).
The reason we started thinking that monoamine oxidase might be involved in the oxidation of amine-free GGOH, a 20-carbon acyclic isoprenol, is that FOH, a 15-carbon acyclic isoprenol in tobacco smoke, has been identified as a selective inhibitor against MAOB (22–24). X-ray crystallography illustrates that FOH is inserted into the substrate-binding pocket of MAOB and is close to the cofactor FAD site, and these authors described that “if the bound trans, trans-farnesol is considered as a substrate mimic, these structural data provide support for the polar nucleophilic mechanism” (22). Hence, we hypothesized that GGOH is one isoprene unit longer than FOH, so that a distance between the 1-CH of GGOH is positioned shorter than the 3.4-Å from the N(5) of the flavin in the binding site of MAOB, which is a distance between the 1-CH of the bound FOH and the N(5) of the flavin in FAD attached to MAOB, and such a topological speculation predicts the 1-CH of GGOH to be oxidized and converted to GGal by the proposed polar nucleophilic attack mechanism (22). We have previously reported that the recombinant hMAOB protein definitely oxidized GGOH to GGal and the activity was inhibited by TCP, an inhibitor of MAO, and the same was true with mitochondrial fractions of HuH-7 cells as enzyme sources (11).

In this study, we decided to show that MAOB enzyme activity is involved in the oxidation reaction from GGOH to GGal using cell culture systems. We first tested whether TCP of the MAO inhibitor inhibits the GGA biosynthetic pathway in a cell-culture system. As described in the Results, TCP induced dose-dependent downregulation of the endogenous GGA content in HuH-7 cells with an IC₅₀ of 33 μM (Fig. 1A). However, the cellular GGA was not completely depleted by TCP treatment even at 100 μM (Fig. 1B and C) and at over 50 μM, the changes in the cellular GGA amount became marginal. Hence, we supposed that some part (roughly 40%) of endogenous GGA was produced by enzymes other than MAOB. After
subtraction of this value, the corrected IC$_{50}$ of TCP was recalculated to be 10.7 µM, which is in the range of the IC$_{50}$ of TCP for MAOB enzyme activity (7.0 µM)(27). It is interesting that a similar proportion of the cellular GGA from exogenous GGOH remained after the 100-µM TCP treatment (Fig. 1D and E). These results indicate that TCP-sensitive enzymes are partly involved in the oxidation of GGOH to GGal to produce the cellular GGA, but we cannot yet conclude that the TCP-sensitive enzyme is MAOB. Because, in addition to MAOB, TCP-sensitive enzymes include MAOA (IC$_{50}$ = 11.5 µM) (27), CYP2A6 (0.42 µM) (28), and CYP2E1 (3.0 µM) (28).

The next knockdown experiment provided additional strong evidence that the MAOB gene is mainly responsible for maintenance of the cellular GGA level in HuH-7 cells. In other words, MAOB siRNA-mediated downregulation caused more than an 80% reduction of not only the endogenous GGA level but also intracellular GGA levels upregulated by either ZAA or exogenous GGOH (Fig. 2), suggesting the greater part of the cellular GGA was produced through MAOB-mediated process. Nevertheless, we still saw that a certain amount of GGA remained in the cells after the downregulation of the MAOB gene.

In the literature (9,11,20,21), several enzymes other than MAOB are reported to be able to produce GGal (Fig. 3A); however, knockdown of these genes did not change the intracellular GGA (Fig. 3B–E), except that knockdown of the PCYOX1 gene significantly and inversely upregulated the GGA level. Although we were able to show how the downregulation of the PCYOX1 gene expression is linked to the upregulation of the cellular GGA level, at present we cannot determine how the downregulation of the PCYOX1 gene resulted in the upregulation of MAOB gene expression (Fig. 3F). Regardless, the cellular levels of endogenous GGA are significantly correlated with the expression levels of the MAOB gene in any
knocked down cells (Fig. 3G).

We are now quite confident that MAOB is a putative enzyme responsible for biosynthesis of GGA in human hepatoma cells. Using LC/MS/MS, we confirmed our previous findings that recombinant human MAOB is active in oxidizing GGOH to GGAl (11). In the present study, we provide additional evidence that MAOB catalyzes the oxidation reaction of acyclic isoprenol by showing that FOH as an additional substrate, but GOH was not oxidized to Gal. Considering that recombinant human MAOA did not oxidize GGOH (11) and the catalytic efficiency \(k_{\text{cat}}/K_{\text{m}}\) of the recombinant hMAOB enzyme was calculated to be approximately 1.7 times greater for GGOH than for geranylgeranylamine (unpublished result), we suggest that the recombinant hMAOB recognizes FOH and GGOH as a specific substrate and catalyzes the oxidation reaction. As for other acyclic isoprenols longer than GGOH, we have not tried to use them as substrates for MAOB.

As a third step, we knocked out the \(MAOB\) gene in the hepatoma cell and attempted to deplete the intracellular GGA, but we failed to deplete it using the knockout method. The \(MAOB\)-knockout Hep3B (Hep3B/\(MAOB\)-KO) cells established by the CRISPR/Cas9-HDR system, drastically reduced both the mRNA and protein levels of the \(MAOB\) gene, as expected. However, the amount of endogenous GGA content in Hep3B/\(MAOB\)-KO cells was unexpectedly not reduced, which is apparently inconsistent with the \(MAOB\)-knockdown-mediated reduction of the endogenous GGA level in HuH-7 cells. Thus, we considered and tested three possibilities: 1) Hep3B cells may produce endogenous GGA using enzyme(s) other than MAOB, which is different from HuH-7 cells. 2) The decrease in the endogenous GGA content in HuH-7 cells by \(MAOB\) siRNA may be due to an off-target effect. 3) When the \(MAOB\) gene is knocked
out, other GGal-producing enzymes may be upregulated to compensate for the absence of MAOB activity, and this putative compensatory mechanism may help maintain the original GGA level in Hep3B/MAOB-KO cells.

Among the three possibilities described above, the first was immediately excluded because introducing MAOB siRNA significantly reduced the intracellular GGA level in Hep3B/MAOB-WT to the same extent as in HuH-7 cells. However, MAOB-siRNA-treated Hep3B/MAOB-KO cells did not change the amount of intracellular GGA, implying that there are no off-targets other than the MAOB gene of the MAOB siRNA used in the present study to refute the second possibility. Finally, to verify the third possibility, we knocked down the other GGal-producing ADH1A and PCYOX1 genes or the MAOA gene in Hep3B/MAOB-KO cells, but we found no change in the cellular GGA content of the knockout cells (see supplemental Fig. S2). At present, a compensatory mechanism for maintaining the GGA concentration in the KO cells has not been proved, but enzymes of the CYP family are under investigation on the premise that a compensatory mechanism does exist.

In this context, the questions of whether MAOB was no longer needed for GGA biosynthesis once putative compensatory mechanisms began to work, or whether MAOB or compensatory mechanism(s) is dominant in GGA biosynthesis. To answer this question, we performed back-transfection of the MAOB gene into Hep3B/MAOB-KO cells to make Hep3B/MAOB-KO/TG cells. As a result, although Hep3B/MAOB-KO/TG cells showed no change in the intracellular GGA content compared with either Hep3B wild-type cells or MAOB-knockout cells, the MAOB-siRNA-mediated knockdown of the transgenic MAOB significantly reduced intracellular GGA levels in Hep3B/MAOB-KO/TG. Thus, the back-
transfection of the \textit{MAOB} gene completely rescued the KO cells from \textit{MAOB}-siRNA insensitivities of endogenous GGA (Fig. 6D). From these results, we conclude that a MAOB-mediated metabolic pathway is a primary process for maintaining the cellular GGA level in human hepatoma cells. Although it was not possible to identify a putative compensatory enzyme in this study, it is absolutely essential to prove it in the future to establish GGA biosynthesis. Whatever compensatory enzyme works in the \textit{MAOB}-KO cells, the existence of a putative maintenance mechanism at the cellular level of endogenous GGA in the \textit{MAOB}-KO cells suggests that GGA is an essential metabolite that has a vital function for cell life other than cell death induction in malignant cells. Indeed, we recently published our observations about another biological function of GGA apart from its function in malignant cells; that is, dietary supplementation with GGA during mating, pregnancy and lactating periods significantly improved the reproduction index in C3H/HeN mice (29) and SAM P1 mice (Shidoji, Y. et al., Japanese patents; see Footnotes for details).

Finally, let us consider why the CRISPR/Cas9-HDR method worked in Hep3B cell line, but failed to knock out the \textit{MAOB} gene in HuH-7 cell line. As for the gene encoding MAOB, of note, there is an important difference between HuH-7 and Hep3B cell lines. The \textit{MAOB} gene localizes to a short arm (Xp11.3) of X-chromosome and a Hep3B cell harbors a single intact X-chromosome (30, 31), whereas in HuH-7 cells, many derivative chromosomes involving X-chromosome [der(X)t(X:14), +der(X)t(X;19), +der(4)t(X;4), der(11)t(X;11), der(13)t(X;13)] and the mosaic copy number observed at Xp are reported (32). These derivative chromosomes may make CRISPR/Cas9-HDR method difficult to knockout the \textit{MAOB} gene in HuH-7 cells. Therefore, we think a molecular mechanism underlying oxidation of GGOH may be the same between these 2 cell lines and the same enzyme system may exist even in normal
hepatocytes.

In conclusion, herein, we show that MAOB is principally involved in GGA biosynthesis through oxidation of GGOH in human hepatoma cells. Historically, it has been established that MAOB is involved in the degradation of catecholamines in the brain (33), and in this context the hepatic-MAOB function is speculated to work in the degradation of amine-containing xenobiotics in bulk, despite its highest expression level. The present study clearly demonstrates that hepatic MAOB has a completely new metabolic role that has not been so far reported. This role is in the biosynthesis of GGA, a biologically active isoprenoid lipid. Therefore, we propose with confidence that hepatic MAOB is also a GGOH oxidase.
Acknowledgments

The authors greatly appreciate Dr. Maiko Mitake, a former graduate student in our laboratory, who provided the preliminary findings of the MAOB knockdown experiment with HuH-7 cells. We also give many sincere thanks to Dr. Hiroshi Sagami for discussion about the possible reaction mechanism of MAOB-catalyzed GGOH oxidation.

This work was supported in part by a grant-in-aid from the Japan Society for the Promotion of Science (grant number16K00862) and a research grant B from the University of Nagasaki.

Conflict of interest:

The authors declare that they have no conflict of interest regarding the contents of this article.
Footnotes

Japanese patent described in the text: Shidoji, Y., Okamoto, K., and Sakane, C. (2011) A livestock feed or a promoter for improving birth rate applied to mammals, a tranquilizer applied to mammals. JP 2011-207802 A 2011.10.20
References

1. Fliesler, S. J., and G. J. Schroepfer. 1983. Metabolism of mevalonic acid in cell-free homogenates of bovine retinas. Formation of novel isoprenoid acids. *J. Biol. Chem.* **258**: 15062–15070.

2. Foster, J. M., J. F. Pennock, I. Marshall, and H. H. Rees. 1993. Biosynthesis of isoprenoid compounds in *Schistosoma mansoni*. *Mol. Biochem. Parasitol.* **61**: 275–284.

3. Araki, H., Y. Shidoji, Y. Yamada, H. Moriwaki, and Y. Muto. 1995. Retinoid agonist activities of synthetic geranyl geranoic acid derivatives. *Biochem. Biophys. Res. Commun.* **209**: 66–72.

4. Muto, Y., H. Moriwaki, M. Ninomiya, S. Adachi, A. Saito, K.T. Takasaki, T. Tanaka, K. Tsurumi, M. Okuno, E. Tomita, T. Nakamura, and T. Kojima. 1996. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. *N. Engl. J. Med.* **334**: 1561–1567.

5. Muto, Y., H. Moriwaki, and A. Saito. 1999. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. *N. Engl. J. Med.* **340**: 1046–1047.

6. Shidoji, Y., and H. Ogawa. 2004. Natural occurrence of cancer-preventive geranylgeranoic acid in medicinal herbs. *J. Lipid Res.* **45**: 1092–1103.

7. Shidoji, Y., and Y. Tabata. 2019. Unequivocal evidence for endogenous geranylgeranoic acid biosynthesized from mevalonate in mammalian cells. *J. Lipid Res.* **60**: 579–593.

8. Bansal, V. S., and S. Vaidya. 1994. Characterization of two distinct allyl pyrophosphatase activities from rat liver microsomes. *Arch. Biochem. Biophys.* **315**: 393–399.

9. Endo, S., T. Matsunaga, C. Ohta, M. Soda, A. Kanamori, Y. Kitade, S. Ohno, K. Tajima, O. El-Kabbani, and A. Hara. 2011. Roles of rat and human aldo–keto reductases in metabolism of farnesol and geranylgeraniol. *Chem. Biol. Interact.* **191**: 261–268.

10. Muraguchi, T., K. Okamoto, M. Mitake, H. Ogawa, and Y. Shidoji. 2011. Polished rice as natural sources of cancer-preventing geranylgeranoic acid. *J. Clin. Biochem. Nutr.* **49**: 8–15.

11. Mitake, M., and Y. Shidoji. 2012. Geranylgeraniol oxidase activity involved in oxidative formation of geranylgeranoic acid in human hepatoma cells. *Biomed. Res.* **33**: 15–24.

12. Konradi, C., P. Riederer, K. Jellinger, and R. Denney. 1987. Cellular action of MAO inhibitors. *J. Neural Transm. Suppl.* **25**: 15–25.

13. Müller, T., and J. Möhr. 2019. Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson’s disease: current status. *Expert Opin. Drug Metab. Toxicol.* **15**: 429–435.

14. Saura, J., J. M. Luque, A. M. Cesura, M. Da Prada, V. Chan-Palay, G. Huber, J. Löffler, and J. G. Richards. 1994. Increased monoamine oxidase b activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. *Neuroscience.* **62**: 15–30.
15. Mallajosyula, J. K., S. J. Chinta, S. Rajagopalan, D. G. Nicholls, and J. K. Andersen. 2009. Metabolic control analysis in a cellular model of elevated MAO-B: relevance to Parkinson’s disease. *Neurotox. Res.* 16: 186–193.

16. Yanez, M., and D. Vina. 2013. Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease. *Curr. Top. Med. Chem.* 13: 1692–1706.

17. Alborghetti, M., and F. Nicoletti. 2019. Different generations of type-B monoamine oxidase inhibitors in Parkinson’s disease: from bench to bedside. *Curr. Neuropharmacol.* 17: 861–873.

18. Fagerberg, L., B. M. Hallström, P. Oksvold, C. Kampf, D. Djureinovic, J. Odeberg, M. Habuka, S. Tahmasebpoor, A. Danielsson, K. Edlund, A. Asplund, E. Sjöstedt, E. Lundberg, C. A.-K. Szigyarto, M. Skogs, J. O. Takanen, H. Berling, H. Tegel, J. Mulder, P. Nilsson, J. M. Schwenk, C. Linskog, F. Danielsson, A. Mardinoglu, Â. Svertsson, K. von Feilitzen, M. Forsberg, M. Zehi, I. Olsson, S. Navani, M. Huss, J. Nielsen, F. Ponten, and M. Uhlén. 2014. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Mol. Cell. Proteomics.* 13: 397–406.

19. Gaweska, H., and P. F. Fitzpatrick. 2011. Structures and mechanism of the monoamine oxidase family. *Biomol. Concepts.* 2: 365–377.

20. Tschantz, W. R., J. A. Dignas, H. J. Pyun, R. M. Coates, and P. J. Casey. 2001. Lysosomal prenylcysteine lyase is a FAD-dependent thioether oxidase. *J. Biol. Chem.* 276: 2321–2324.

21. Lu, J.-Y., and S. L. Hofmann. 2006. Thematic review series: Lipid posttranslational modifications. Lysosomal metabolism of lipid-modified proteins. *J. Lipid Res.* 47: 1352–1357.

22. Hubálek, F., C. Binda, A. Khalil, M. Li, A. Mattevi, N. Castagnoli, and D. E. Edmondson. 2005. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. *J. Biol. Chem.* 280: 15761–15766.

23. Khalil, A. A., B. Davies, and N. Castagnoli. 2006. Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke. *Bioorg. Med. Chem.* 14: 3392–3398.

24. Sari, Y., and A. Khalil. 2015. Monoamine oxidase inhibitors extracted from tobacco smoke as neuroprotective factors for potential treatment of Parkinson’s disease. *CNS Neurol. Disord. - Drug Targets.* 14: 777–785.

25. Okita, K., N. Izumi, O. Matsu, K. Tanaka, S. Kaneko, H. Moriwaki, K. Ikeda, Y. Osaka, K. Numata, K. Nakachi, N. Kokudo, K. Imanaka, S. Nishiguchi, T. Okusaka, Y. Nishigaki, S. Shomi, M. Kudo, K. Ido, Y. Karino, N. Hayashi, Y. Ohashi, M. Makuuchi, and H. Kumada. 2014. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a
randomized double-blind placebo-controlled study. *J. Gastroenterol.* **50**: 191–202.

26. Okita, K., N. Izumi, K. Ikeda, Y. Osaki, K. Numata, M. Ikeda, N. Kokudo, K. Imanaka, S. Nishiguchi, S. Kondo, Y. Nishigaki, S. Shiomi, K. Ueshima, N. Isoda, Y. Karino, M. Kudo, K. Tanaka, S. Kaneko, H. Moriwaki, M. Makuuchi, T. Okusaka, N. Hayashi, Y. Ohashi, and H. Kumada. 2015. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. *J. Gastroenterol.* **50**: 667–674.

27. Ji, Y.-Y., S.-D. Lin, Y.-J. Wang, M.-B. Su, W. Zhang, H. Gunosewoyo, F. Yang, J. Li, J. Tang, Y.-B. Zhou, and L.-F. Yu. 2017. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors. *Eur. J. Med. Chem.* **141**: 101–112.

28. Taavitsainen, P., R. Juvonen, and O. Pelkonen. 2001. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. *Drug Metab. Dispos.* **29**: 217–222.

29. Tabata, Y., S. Uematsu, and Y. Shidoji. 2019. Supplementation with geranylgeranoic acid during mating, pregnancy and lactation improves reproduction index in C3H/HeN mice. *J. Pet Anim. Nutr.* (in press)

30. Wong, N., P. Lai, T. W-T.Leung, J. W-Y.Lau, and P.M. Johnson. 2000. A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping. *Hepatology.* **32**: 1060-1068.

31. Gray, S.G., S. Kytolä, W.O. Lui, C. Larsson, and T.J. Ekström. 2000. Modulating IGFBP-3 expression by trichostatin A: Potential therapeutic role in the treatment of hepatocellular carcinoma. *Int. J. Mol. Med.* **5**: 33-41.

32. Kasai, F., N. Hirayama, M. Ozawa, M. Satoh, and A. Kohara. 2018. HuH-7 reference genome profile: complex karyotype composed of massive loss of heterozygosity. *Human Cell.* **31**: 261-267.

33. Oertel, W., and J. B. Schulz. 2016. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. *J. Neurochem.* **139**: 325–337.
Figures and figure legends

Figure 1. Tranlylcypromine-induced downregulation of cellular GGA levels in HuH-7 cells.

A, Dose-dependent changes of endogenous GGA level in HuH-7 cells after treatment with 0–100 μM of TCP for 24 h. The amount of the intracellular GGA represents the mean ± SD of three measurements. The IC$_{50}$ of TCP was obtained using GraphPad Prism 7.0. B–E, LC/MS/MS chromatograms of the lipid extracts from the nontreated control HuH-7 cells (B), cells treated for 48 h with 100 μM TCP (C), with 25 μM GGOH for 24 h (D) and the cells treated for 24 h with 25 μM GGOH after 24-h pretreatment with 100 μM TCP (E). The arrows indicate the elution position of the authentic GGA. The vertical axes of the chromatograms show a signal intensity of 85 as 100% (B and C), and 2210 as 100% (D and E).
Figure 2. \(MAOB\) siRNA-induced downregulation of cellular GGA levels in HuH-7 cells.

A, Total RNA was prepared from HuH-7 cells after 72-h incubation with each siRNA to measure the cellular levels of \(MAOB\) mRNA by RT-qPCR. Each bar represents the mean ± SEM (n = 3). 

B, C, and D, LC/MS/MS chromatograms of the lipid extract from each sample treated as described as follows. After HuH-7 cells were incubated with each siRNA for 96 h, the cells were incubated for another 24 h in the absence (B) or presence of 25 µM GGOH (C) or 15 µM ZAA (D). The arrows indicate the elution position of authentic GGA. The vertical axes of the chromatograms show a signal intensity of 60 as 100% (B), 1460 as 100% (C) and 246 as 100% (D). **, \(p < 0.01\) compared with control (siCtrl).
A. Geranylgeranylated protein → Geranylgeranyl-cysteine

GGPP → GGOH → GGal → GGA

B. 

C. 

D. 

E. 

F. 

G. 

Relative abundance of MAOB mRNA

Cellular levels of GGA (pmol/g)

$R^2 = 0.8465$
Figure 3 Knockdown of MAOA, PCYOX1, and ADH1A genes using each siRNA in HuH-7 cells does not induce a decrease in endogenous GGA level.

A, According to the literature, possible metabolic pathways to produce GGal are depicted in addition to oxidation of GGOH to GGal catalyzed by MAOB.

B, C and D, Total RNA was prepared after HuH-7 cells were incubated with each siRNA for 72 h to measure the cellular levels of MAOA, PCYOX1 and ADH1A mRNA by RT-qPCR. Each bar represents the mean ± SEM (n = 3).

E, LC/MS/MS chromatograms of the lipid extract from HuH-7 cells incubated with control siRNA (siCtrl), MAOA siRNA (siMAOA), PCYOX1 siRNA (siPCYOX1), or ADH1A siRNA (siADH1A) for 120 h. The chromatograms show a peak height of 58 as 100% (siCtrl, siMAOA, siADH1A), and 84 as 100% (siPCYOX1).

F, The expression level of MAOB mRNA in HuH-7 cells knocked down with each siRNA. Each bar represents the mean ± SEM (n = 3).

G, Correlation between MAOB mRNA expression level and intracellular GGA level in HuH-7 cells knocked down with each siRNA. *, p < 0.05 compared with control (siCtrl). **, p < 0.01 compared with control (siCtrl) (t-test).
Figure 4. Recombinant human MAOB catalyzes oxidation of GGOH and FOH to GGal and Fal, respectively.

LC/MS/MS elution profiles of ethanol extracts after incubation of the recombinant hMAOB with 25 µM GOH (A), 25 µM FOH (B) or 25 µM GGOH (C) at 37°C for 1 h. The elution position of authentic each aldehyde was indicated by arrows. D. The increasing concentrations of GGOH or FOH were incubated with 0.25 U hMAOB at 37°C for 1 h. The amounts of GGal or Fal products were measured by LC/MS/MS analysis. Values of $K_m$ were obtained by fitting plots of amounts of GGal or Fal products versus GGOH or FOH concentration, respectively, using GraphPad prism 7. Each point represents the mean ± SD (n = 3). FT, flow through.
**Panel A**

MAOB mRNA expression level relative to 28S rRNA normalized by MAOB/WT value.

**Panel B**

MAOB protein expression level relative to GAPDH.

**Panel C**

Relative intensity of signals (% of maximum height) for m/z: 303 → 98.

**Panel D**

Cellular levels of GGA (pmol/g).

**Panel E**

Cellular levels of GGA (pmol/g).
Figure 5. Knockout of MAOB by the CRISPR/Cas9-HDR system in Hep3B cells significantly reduces the cellular level of both MAOB mRNA and protein, but does not induce a decrease of intracellular GGA.

A, MAOB mRNA expression level in MAOB knockout cells established by the CRISPR/Cas9-HDR system and wild-type Hep3B cells. Each bar represents the mean ± SEM (n = 3). B, Total RIPA cell lysates of Hep3B MAOB-WT cells and Hep3B MAOB-KO cells were analyzed by western blotting to measure the level of MAOB. N.S. is a non-specific band. Each bar in the right panel represents the mean ± SEM (n = 3) of the relative intensity of the MAOB band. C, LC/MS/MS chromatograms of the lipid extract from Hep3B/MAOB-WT and Hep3B/MAOB-KO. The vertical axes of both chromatograms show signal intensity of 184 as 100%. D, The relative expression levels of MAOB mRNA to that of siCtrl-treated Hep3B/MAOB-WT cells upon MAOB siRNA treatment in Hep3B/MAOB-WT or Hep3B/MAOB-KO for 72 h. Each bar represents the mean ± SEM (n = 3). E, The endogenous GGA levels of the lipid extract from Hep3B/MAOB-WT or Hep3B/MAOB-KO after incubation with MAOB siRNA for 120 h. The amount of the intracellular GGA represents the mean ± SD of three measurements. *, p < 0.05 compared with control (Hep3B/MAOB-WT siCtrl). **, p < 0.01 compared with control (Hep3B/MAOB-WT siCtrl).
Figure 6. Rescue of MAOB siRNA sensitivity of the cellular GGA level in Hep3B/MAOB-KO cells by transgenic MAOB expression.

A, Total RIPA cell lysates of Hep3B/MAOB-KO, Hep3B/MAOB-KO/TG and Hep3B/MAOB-WT were analyzed by western blotting with an anti-MAOB antibody. GAPDH was analyzed as a loading control. Each bar in the right panel represents the mean ± SEM (n = 3) of the relative intensity of the MAOB band to that of the corresponding GAPDH band. B, The relative expression levels of MAOB mRNA upon MAOB siRNA treatment in Hep3B/MAOB-WT, Hep3B/MAOB-KO or Hep3B/MAOB-KO/TG. Each bar represents the mean ± SEM (n = 3). C, The endogenous GGA levels in the lipid extract from Hep3B/MAOB-WT, Hep3B/MAOB-KO, or Hep3B/MAOB-KO/TG incubated with MAOB siRNA or control siRNA for 120 h. Each bar represents the mean ± SEM (n = 3). D, Changes in intracellular GGA level by MAOB siRNA treatment in Hep3B/MAOB-WT, Hep3B/MAOB-KO or Hep3B/MAOB-KO/TG. The amount of intracellular GGA represents an as % of the control (the mean ± SD of three measurements). *, p < 0.05 compared with control. **, p < 0.01 compared with control (ANOVA with post hoc Scheffe).